Product logins

Find logins to all Clarivate products below.


Renal Anemia in Chronic Kidney Disease Non-Dialysis | Chart Trends | US | 2014

This report leverages physician insights as well as patient chart data to provide the most up-to-date information about chronic kidney disease non-dialysis (CKD-ND) patient care in the US, including referral patterns, patient demographics, the use of laboratory assessments, and the use of medications. In particular, our in-depth analysis of CKD-ND medications spans a wide range of variables including product initiation, dosing, switching, and crossovers; coverage has also been expanded in 2014 to include not only erythropoiesis stimulating agents (ESAs), IV and oral iron, but also phosphate binders, vitamin D, calcimimetic, diabetic agents, as well as a new section on products in development for renal anemia. Finally, by comparing what nephrologists report about patient care to actual patient records, gaps in intended versus actual care are uncovered and opportunities for the expanded use of CKD-ND treatments become more clearly defined.

Related Market Assessment Reports

Report
Chronic Kidney Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Kidney Disease (US)
Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises therapies, which are…
Report
Asthma – Unmet Need – Unmet Need – Severe Asthma (US/EU)
Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the availability of LAMAs (e.g., Boehringer…
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. Symptoms range from general malaise to serious renal and CNS manifestations…
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
Report
Asthma – Access & Reimbursement – Access & Reimbursement – Asthma (US)
The dynamics within the LABA/ICS FDC, LAMA, LABA/LAMA/ICS FDC, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS FDCs (e.g., GSK’s…